MRI Contrast Clearance Analysis for Glioma Grading and Genotyping
1 other identifier
observational
100
1 country
1
Brief Summary
Gliomas are the most common primary brain tumor. Gliomas with different grades have different clinical behaviors that determine treatment planning and patient prognosis in clinical practice. In the 2021 World Health Organization (WHO) classification of tumors for the central nervous system, glioma genotyping was considered the most relevant information for neuroradiologists. The isocitrate dehydrogenase (IDH) genotype and 1p/19q codeletion status are two essential molecular markers that divide glioma into three groups: IDH wild-type, IDH mutant with 1p/19q non-codeletion, and IDH mutant with 1p/19q codeletion. MRI contrast clearance analysis (CCA) is based on T1 delayed-contrast subtraction map, Blue/tumor regions in CCA represent efficient clearance of contrast from the tissue (delayed signal\<early signal), while red/nontumor regions in CCA represent contrast accumulation (delayed signal\>early signal). However, there are not any reports on the role of MRI CCA in glioma grading and genotyping, Thus, We hypothesized that the proportion of blue/red region and their histogram analyses, which could be acquired for predicting IDH genotypes and 1p/19q codeletion in gliomas, and to assess the application of CCA in glioma grading.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2023
CompletedFirst Submitted
Initial submission to the registry
August 24, 2023
CompletedFirst Posted
Study publicly available on registry
August 31, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedAugust 31, 2023
August 1, 2023
7 months
August 24, 2023
August 29, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Proportion of bule/red ROI
The common vessels morphology in the blue region was undamaged vessel lumens which exists in active tumor, while vessels in the red regions presented different stages of vessel necrosis.
Through study completion, an average of 1 year
Histogram of bule/red ROI
The bule and red ROI from CCA histogram analysis included1st、10th 、90th and 99th percentiles, mean, median, variance, skewness, and kurtosis.
Through study completion, an average of 1 year
Eligibility Criteria
The subjects are not restricted by gender and age. For details, please refer to the "criteria" column.
You may qualify if:
- Patients with brain space -occupying lesions, have not yet undergone antitumor therapy;
- MRI with T1-contract delayed sequence was performed less than 2 weeks before surgery;
- Definite histopathologic diagnosis of glioma.
You may not qualify if:
- WHO 1 gliomas and other non-glioma brain tumors;
- Poor image quality and heavy artifact affect the subsequent image processing.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sang Zifan
Chongqing, Chongqing Municipality, 400042, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of radiology department
Study Record Dates
First Submitted
August 24, 2023
First Posted
August 31, 2023
Study Start
June 1, 2023
Primary Completion
December 31, 2023
Study Completion
June 30, 2024
Last Updated
August 31, 2023
Record last verified: 2023-08